世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
放射性医薬品市場。世界の産業動向、シェア、サイズ、成長、機会、そして2021-2026年の予測Radiopharmaceuticals Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026 The global radiopharmaceuticals market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 7% during 2021-2026. Keeping in mind the unce... もっと見る
サマリーThe global radiopharmaceuticals market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient’s body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones. Radiopharmaceuticals Market Trends: The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market. Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales. Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth. Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global radiopharmaceuticals market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, application and end use. Breakup by Product Type: Diagnostic Nuclear Medicine Therapeutic Nuclear Medicine Breakup by Application: Oncology Cardiology Neurology Endocrinology Others Breakup by End Use: Hospitals and Clinics Research Institutes Diagnostic Centers Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG. Key Questions Answered in This Report: How has the global radiopharmaceuticals market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global radiopharmaceuticals market? What are the key regional markets? What is the breakup of the market based on the product type? What is the breakup of the market based on the application? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global radiopharmaceuticals market and who are the key players? What is the degree of competition in the industry? 目次1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Radiopharmaceuticals Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product Type 6.1 Diagnostic Nuclear Medicine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Therapeutic Nuclear Medicine 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Application 7.1 Oncology 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Cardiology 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Neurology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Endocrinology 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospitals and Clinics 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Research Institutes 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Diagnostic Centers 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Advanced Accelerator Applications (Novartis AG) 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.2 Bayer AG 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bracco S.p.A. 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 SWOT Analysis 14.3.4 Cardinal Health Inc. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis 14.3.5 Curium Pharma 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.6 General Electric Company 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 IBA RadioPharma Solutions 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Jubilant Pharma Limited 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.9 Lantheus Medical Imaging Inc 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.10 Nordion Inc. (Sotera Health) 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 SWOT Analysis 14.3.11 NTP Radioisotopes SOC Ltd 14.3.11.1 Company Overview 14.3.11.2 Product Portfolio 14.3.12 PharmaLogic Holdings Corp. 14.3.12.1 Company Overview 14.3.12.2 Product Portfolio 14.3.13 Siemens AG 14.3.13.1 Company Overview 14.3.13.2 Product Portfolio 14.3.13.3 Financials 14.3.13.4 SWOT Analysis
SummaryThe global radiopharmaceuticals market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient’s body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones. Radiopharmaceuticals Market Trends: The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market. Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales. Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth. Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans. Key Market Segmentation: IMARC Group provides an analysis of the key trends in each sub-segment of the global radiopharmaceuticals market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on product type, application and end use. Breakup by Product Type: Diagnostic Nuclear Medicine Therapeutic Nuclear Medicine Breakup by Application: Oncology Cardiology Neurology Endocrinology Others Breakup by End Use: Hospitals and Clinics Research Institutes Diagnostic Centers Breakup by Region: North America United States Canada Asia-Pacific China Japan India South Korea Australia Indonesia Others Europe Germany France United Kingdom Italy Spain Russia Others Latin America Brazil Mexico Others Middle East and Africa Competitive Landscape: The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG. Key Questions Answered in This Report: How has the global radiopharmaceuticals market performed so far and how will it perform in the coming years? What has been the impact of COVID-19 on the global radiopharmaceuticals market? What are the key regional markets? What is the breakup of the market based on the product type? What is the breakup of the market based on the application? What is the breakup of the market based on the end use? What are the various stages in the value chain of the industry? What are the key driving factors and challenges in the industry? What is the structure of the global radiopharmaceuticals market and who are the key players? What is the degree of competition in the industry? Table of Contents1 Preface2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Radiopharmaceuticals Market 5.1 Market Overview 5.2 Market Performance 5.3 Impact of COVID-19 5.4 Market Forecast 6 Market Breakup by Product Type 6.1 Diagnostic Nuclear Medicine 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Therapeutic Nuclear Medicine 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Application 7.1 Oncology 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Cardiology 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Neurology 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Endocrinology 7.4.1 Market Trends 7.4.2 Market Forecast 7.5 Others 7.5.1 Market Trends 7.5.2 Market Forecast 8 Market Breakup by End Use 8.1 Hospitals and Clinics 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Research Institutes 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Diagnostic Centers 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by Region 9.1 North America 9.1.1 United States 9.1.1.1 Market Trends 9.1.1.2 Market Forecast 9.1.2 Canada 9.1.2.1 Market Trends 9.1.2.2 Market Forecast 9.2 Asia-Pacific 9.2.1 China 9.2.1.1 Market Trends 9.2.1.2 Market Forecast 9.2.2 Japan 9.2.2.1 Market Trends 9.2.2.2 Market Forecast 9.2.3 India 9.2.3.1 Market Trends 9.2.3.2 Market Forecast 9.2.4 South Korea 9.2.4.1 Market Trends 9.2.4.2 Market Forecast 9.2.5 Australia 9.2.5.1 Market Trends 9.2.5.2 Market Forecast 9.2.6 Indonesia 9.2.6.1 Market Trends 9.2.6.2 Market Forecast 9.2.7 Others 9.2.7.1 Market Trends 9.2.7.2 Market Forecast 9.3 Europe 9.3.1 Germany 9.3.1.1 Market Trends 9.3.1.2 Market Forecast 9.3.2 France 9.3.2.1 Market Trends 9.3.2.2 Market Forecast 9.3.3 United Kingdom 9.3.3.1 Market Trends 9.3.3.2 Market Forecast 9.3.4 Italy 9.3.4.1 Market Trends 9.3.4.2 Market Forecast 9.3.5 Spain 9.3.5.1 Market Trends 9.3.5.2 Market Forecast 9.3.6 Russia 9.3.6.1 Market Trends 9.3.6.2 Market Forecast 9.3.7 Others 9.3.7.1 Market Trends 9.3.7.2 Market Forecast 9.4 Latin America 9.4.1 Brazil 9.4.1.1 Market Trends 9.4.1.2 Market Forecast 9.4.2 Mexico 9.4.2.1 Market Trends 9.4.2.2 Market Forecast 9.4.3 Others 9.4.3.1 Market Trends 9.4.3.2 Market Forecast 9.5 Middle East and Africa 9.5.1 Market Trends 9.5.2 Market Breakup by Country 9.5.3 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Advanced Accelerator Applications (Novartis AG) 14.3.1.1 Company Overview 14.3.1.2 Product Portfolio 14.3.2 Bayer AG 14.3.2.1 Company Overview 14.3.2.2 Product Portfolio 14.3.2.3 Financials 14.3.2.4 SWOT Analysis 14.3.3 Bracco S.p.A. 14.3.3.1 Company Overview 14.3.3.2 Product Portfolio 14.3.3.3 SWOT Analysis 14.3.4 Cardinal Health Inc. 14.3.4.1 Company Overview 14.3.4.2 Product Portfolio 14.3.4.3 Financials 14.3.4.4 SWOT Analysis 14.3.5 Curium Pharma 14.3.5.1 Company Overview 14.3.5.2 Product Portfolio 14.3.6 General Electric Company 14.3.6.1 Company Overview 14.3.6.2 Product Portfolio 14.3.6.3 Financials 14.3.6.4 SWOT Analysis 14.3.7 IBA RadioPharma Solutions 14.3.7.1 Company Overview 14.3.7.2 Product Portfolio 14.3.8 Jubilant Pharma Limited 14.3.8.1 Company Overview 14.3.8.2 Product Portfolio 14.3.9 Lantheus Medical Imaging Inc 14.3.9.1 Company Overview 14.3.9.2 Product Portfolio 14.3.9.3 Financials 14.3.10 Nordion Inc. (Sotera Health) 14.3.10.1 Company Overview 14.3.10.2 Product Portfolio 14.3.10.3 SWOT Analysis 14.3.11 NTP Radioisotopes SOC Ltd 14.3.11.1 Company Overview 14.3.11.2 Product Portfolio 14.3.12 PharmaLogic Holdings Corp. 14.3.12.1 Company Overview 14.3.12.2 Product Portfolio 14.3.13 Siemens AG 14.3.13.1 Company Overview 14.3.13.2 Product Portfolio 14.3.13.3 Financials 14.3.13.4 SWOT Analysis
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（産業機械）の最新刊レポート
IMARC Services Private Limited.社のその他分野での最新刊レポート
本レポートと同じKEY WORD（industry）の最新刊レポート
よくあるご質問IMARC Services Private Limited.社はどのような調査会社ですか?インドに調査拠点を持つ調査会社。幅広い分野をカバーしていますがケミカルに特に焦点を当てています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/27 10:26 153.88 円 161.83 円 196.22 円 |
